Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

At 24 weeks, RCT (n=213) reported improved HbA1c with imeglimin, a first-in-class oral antidiabetic which improves mitochondrial function, vs placebo (mean difference in change from baseline HbA1c was −0.87%; −9.5 mmol/mol; P < 0.0001).

Diabetes Care